Michael Fernando

Cooley advised Advanced Instruments, a subsidiary of Patricia Industries and a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, on intellectual property and licensing aspects in connection with its definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised Hummingbird Bioscience, a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases, on its exclusive worldwide license agreement with Callio Therapeutics, a newly launched biotech company focused on realizing the promise of multipayload antibody-drug conjugates (ADCs) to improve cancer therapy.

Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to $380 million, including an upfront payment of $270 million.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.